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ABSTRACT
Chronic obstructive pulmonary disease (COPD) is one of the most
common respiratory diseases and a major cause of morbidity and
mortality worldwide. Disturbed innate immune processes char-
acterize the pathogenesis of COPD. Vitamin D deficiency is very
common in COPD patients and has been associated with disease
severity. Interestingly, mechanistic evidence from animal and in vitro
studies has demonstrated important innate immunomodulatory
functions of vitamin D, including anti-inflammatory, antioxidative, and
antimicrobial functions. This review discusses in detail how the innate
immunomodulatory functions of vitamin D may have therapeutic
potential in COPD patients. The remaining challenges associated
with vitamin D therapy in COPD patients are also discussed.
Introduction
Chronic obstructive pulmonary disease (COPD) is a chronic
disease characterized by progressive expiratory airflow limita-
tion, which is not fully reversible (Decramer et al., 2012).
Cigarette smoking is themajor risk factor for COPD. Currently,
COPD is the fourth leading cause of death worldwide, while
prevalence and mortality rates are still increasing. With
progression of the disease, COPD patients become more
susceptible to exacerbations, which are primarily caused by
respiratory bacterial and viral infections (Wedzicha and Seemungal,
2007). COPD exacerbations are an important cause of hospital-
ization, reduced quality of life, and mortality. When presenting
with an acute exacerbation, COPD patients are often treated
with inhaled corticosteroids. However, the majority of COPD
patients appear to be resistant to the anti-inflammatory effects
of corticosteroids (Culpitt et al., 2003; Barnes, 2013).
The pathophysiology of COPD includes small airway disease
(or chronic bronchiolitis), characterized by thickening and fibrosis
of small airways, and emphysema, both of which contribute to
airflow limitation. In COPD patients, the airflow limitation is
associated with an abnormal inflammatory response in the
airways and lung parenchyma. The inflammatory response
involves both innate immune cells (neutrophils, macrophages)
and adaptive immune cells (T and B lymphocytes) but also in-
volves the activation of structural cells, including airway epithelial
cells (Barnes, 2014). Inhaled cigarette smoke induces pulmonary
inflammation through activation of proinflammatory pathways,
including the nuclear factor-kB (NF-kB) pathway and the p38
mitogen-activated protein kinase (MAPK) pathway. The oxidative
stress resulting from cigarette smoke and inflammatory cells
further amplifies the inflammation in COPD (Kirkham and
Barnes, 2013). In addition to enhanced pulmonary inflammation
and oxidative stress, COPD is characterized by an impaired host
defense in the lungs (Berenson et al., 2006; Taylor et al., 2010).
This impairment potentially leads to increased bacterial
colonization of the lower airways, whichmay in turn predispose
COPD patients to acute exacerbations.
With the discovery of important immunomodulatory prop-
erties of vitamin D, interest in a potential role for vitamin D in
COPD therapy has increased over the years. VitaminDdeficiency
(defined as serum 25-hydroxyvitamin D ,20 ng/ml) has been
shown to be highly prevalent in COPD patients, and it correlates
with disease severity, as assessed by forced expiratory volume in
1 second (FEV1) (Janssens et al., 2010; Persson et al., 2012; Berg
et al., 2013; Romme et al., 2013). Low serum levels of vitamin D
have been associatedwith characteristic disease features of COPD,
including reduced and faster lung function decline (Black and
Scragg, 2005; Janssens et al., 2010; Lange et al., 2012; Berg et al.,
2013; Afzal et al., 2014), severity of computed tomography–defined
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glucocorticosteroid; IKK, IkB kinase; IL, interleukin; LPS, lipopolysaccharide; MAPK, mitogen-activated protein kinase; MKP, MAPK phosphatase;
MMP, matrix metalloproteinase; NF-kB, nuclear factor-kB; Nrf2, nuclear factor erythroid 2-related factor 2; TEI-A00114, (5Z,7E)-(1S,3R)-20(R)-[(5E)-
(2S)-2-hydroxy-2-methyl-cyclopentanone-5-ylidene]methyl-9,10-secopregna-5,7,10(19)-triene-1,3-diol; TGF-b, transforming growth factor-b; TX527,
19-nor-14,20-bisepi-23-yne-1,25(OH)2D3; VDR, vitamin D receptor.
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emphysema (Berg et al., 2013), an increased risk of upper
respiratory infections (Cannell et al., 2006; Ginde et al., 2009),
and COPD exacerbation (Lehouck et al., 2012; Heulens et al.,
2013). Although an intervention trial with vitamin D supple-
mentation in COPD patients did not show an overall effect on
exacerbation rates, a post-hoc analysis did reveal that vitamin D
supplementation may significantly reduce the number of
exacerbations in COPD patients with severe vitamin D de-
ficiency (25-hydroxyvitamin D ,10 ng/ml) at baseline (Lehouck
et al., 2012). The observed benefit of vitamin D supplementation
in COPD patients with established vitamin D deficiency was
confirmed by the Vitamin D Supplementation in Patients with
Chronic Obstructive Pulmonary Disease (ViDiCo) trial, which
demonstrated a clinically and statistically significant reduction
of moderate to severe exacerbations (Martineau et al., 2015).
Abundant mechanistic in vitro as well as in vivo animal
studies suggest a potential involvement of vitamin D in various
pathogenic processes in COPD, as shown in Fig. 1. In this
review, we discuss how vitamin D could be a therapeutic agent
in COPD through its effect on inflammation, antimicrobial
responses, lung remodeling, and oxidative stress as well as its
impact on the anti-inflammatory effects of corticosteroids. Al-
though vitamin D has been shown to play an important role in
adaptive immunity, we emphasize the effect of vitamin D on
pulmonary innate immunity (alveolar macrophages, neutro-
phils, and airway epithelial cells), which constitutes the driv-
ing force of perpetuating inflammation in COPD. Finally,
we will discuss the challenges associated with the use of
vitamin D therapy as an anti-inflammatory agent in COPD
patients.
Fig. 1. Potential therapeutic innate immune targets for vitamin D in the pathogenesis of COPD. Cigarette smoke activates epithelial cells and alveolar
macrophages, leading to the activation of major inflammatory pathways, including NF-kB and p38 MAPK pathways. Activation of these intracellular
pathways results in the production of several cytokines and chemokines, which attract inflammatory cells (neutrophils, T cells, and monocytes) to the
lungs. Cigarette smoke itself and activated inflammatory cells contribute to oxidative stress in the airways of COPD patients. Several cell types,
including neutrophils and alveolar macrophages, release proteases, which break down connective tissue and thereby contribute to emphysema.
Moreover, epithelial cells release TGF-b, which stimulates the proliferation of fibroblasts and consequently fibrosis in the small airways, resulting in
small airway disease (chronic bronchiolitis). In COPD, the phagocytic function of alveolar macrophages has been shown to be defective, potentially
resulting in increased bacterial colonization of COPD airways. Vitamin D may have therapeutic potential in COPD by inhibition of TGF-b signaling,
inhibition of the NF-kB and p38 MAPK pathways and production of inflammatory cytokines and chemokines, inhibition of oxidative stress, stimulation
of antimicrobial peptide production, and potentially stimulation of the phagocytic capacity of alveolar macrophages.
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Effect of Vitamin D on Important Pathogenic
Processes in COPD
Local Vitamin D Metabolism in the Innate Immune
System. Vitamin D is obtained primarily through conversion
of 7-dehydrocholesterol in the skin by UV light and to a lesser
extent from the diet. Activation of vitamin D requires two
hydroxylations. The first hydroxylation occurs in the liver
and leads to the production of 25-hydroxyvitamin D, the main
circulating form of vitamin D and determinant of vitamin D
status. Subsequently, 25-hydroxyvitamin D is converted
by CYP27B1 (1a-hydroxylase) into the biologically active
1,25-dihydroxyvitamin D, which occurs mainly in the kidneys.
1,25-Dihydroxyvitamin D exerts its biologic functions by binding
to the vitamin D receptor (VDR). After ligand binding, a hetero-
dimer is formed with the retinoid X receptor, and this vitamin D
receptor–retinoid X receptor complex binds to specific genomic
sequences (vitamin D response elements) in the promoter region
of target genes, whereby gene expression is regulated.
In addition to this well known genomic signaling, 1,25-
dihydroxyvitamin D can also exert nongenomic actions by interact-
ing with signaling pathways outside the nucleus (Losel and
Wehling, 2003). In the kidneys, expression of CYP27B1 and
thus 1,25-dihydroxyvitamin D production is strictly regulated
by calcium, phosphorus, and their regulating hormones (in-
cluding parathyroid hormone), thereby maintaining calcium
and bone metabolism. Negative feedback is provided by 1,25-
dihydroxyvitaminD itself through downregulation of CYP27B1
and upregulation of CYP24A1 (24-hydroxylase) (which cata-
lyzes the first step in vitamin D catabolism), thereby prevent-
ing the excessive production of 1,25-dihydroxyvitamin D.
Expression of both CYP27B1 and VDR has been found in
various cell types of the lung innate immune system, including
airway epithelial cells, macrophages, and neutrophils (Provvedini
et al., 1983; Monkawa et al., 2000; Overbergh et al., 2000;
Takahashi et al., 2002; Hansdottir et al., 2008). Consequently,
conversion of 25-hydroxyvitamin D into the biologically active
1,25-dihydroxyvitamin D can occur locally in the lungs and in
this way act in an autocrine or paracrine fashion to exert its
immunomodulatory functions. In sharp contrast to the renal
regulation of CYP27B1, the expression of CYP27B1 in immune
cells is controlled by immune signals. For example, in monocytes/
macrophages, CYP27B1 expression is upregulated by interferon-g,
lipopolysaccharide (LPS), and Toll-like receptor 2/1 ligands
(Overbergh et al., 2000; Esteban et al., 2004; Liu et al., 2006).
In further contrast with the renal control of 1,25-
dihydroxyvitamin D production, negative feedback control by
1,25-dihydroxyvitamin itself is lacking in immune cells. In this
regard, expression of CYP27B1 in immune cells is not sup-
pressed by 1,25-dihydroxyvitamin D (Overbergh et al., 2000).
Finally, it has been shown that macrophages express a
truncated, catabolically inactive form of CYP24A1, thereby
preventing catabolism of 1,25-dihydroxyvitamin D (Ren et al.,
2005). The latter suggests that macrophages are able to maintain
an overproduction of 1,25-dihydroxyvitamin D, which could
promote innate effector functions. Aside from the vast amount
of studies on myeloid-derived cells, little is known about the
mechanisms regulating vitamin D metabolism in airway epithe-
lial cells.
How Could Vitamin D Influence Lung Inflammation
in COPD? Recognition of particles from cigarette smoke by
airway epithelial cells and alveolar macrophages results in
the activation of intracellular signaling pathways, including
the NF-kB and p38 MAPK pathways. The activity of both
NF-kB and p38 MAPK is enhanced in the epithelial cells and
alveolar macrophages of COPD patients (Di Stefano et al.,
2002; Caramori et al., 2003; Rajendrasozhan et al., 2008;
Renda et al., 2008). These pathways are pivotal in driving the
inflammatory response in COPD patients and, once activated,
lead to the enhanced secretion of a number of inflammatory
cytokines and chemokines, including interleukin-1b (IL-1b),
IL-6, IL-8, tumor necrosis factor-a, and monocyte chemoattractant
protein-1. In response to these inflammatory signals, neutrophils,
monocytes, and T lymphocytes rapidly migrate into the lungs and
further promote the inflammatory response.
Interestingly, the active form of vitamin D has been shown
to exert anti-inflammatory effects by inhibiting NF-kB and
MAPK activity (Takahashi et al., 2002; Hansdottir et al., 2010;
Zhang et al., 2012) (Fig. 1). In the inactive state, NF-kB is
sequestered in the cytoplasm by interaction with IkB.Upon cell
activation by proinflammatory stimuli, IkB is phosphorylated
by IkB kinase (IKK), leading to the degradation of IkB by the
proteasome. Subsequently, free NF-kB can translocate to the
nucleus where it activates transcription of several proinflamma-
tory cytokines (e.g., IL-6, IL-8, tumor necrosis factor-a).
Severalmechanismshave been proposed to explain howvitaminD
could counteract the activity of NF-kB. For example, in vitro
1,25-dihydroxyvitamin D inhibited the translocation of the NF-kB
complex to the nucleus in several cell types, including macro-
phages and airway epithelial cells, either by upregulation of
IkB expression (Riis et al., 2004; Cohen-Lahav et al., 2006;
Hansdottir et al., 2010) or by direct interaction of 1,25-
dihydroxyvitamin D-VDR with IKK, thereby blocking IKK
activity (Chen et al., 2013). However, vitamin D could also inhibit
the binding of NF-kB toDNA and in this waymay interfere in the
transcriptional activity of NF-kB (D’Ambrosio et al., 1998; Harant
et al., 1998).
Another central transducer of inflammatory signals leading
to the activation of several transcription factors is the p38
MAPK pathway. In this regard, inhibition of p38MAPK activity
in monocytes by 1,25-dihydroxyvitamin D was linked to the
induction of MAPK phosphatase-1 (MKP-1), which dephosphor-
ylates p38 and inhibits its subsequent activation (Zhang et al.,
2012). A similar mechanism was found in prostate cells where
induction ofMKP-5 by 1,25-dihydroxyvitaminDwas responsible
for inhibition of p38 MAPK activity (Nonn et al., 2006).
The inhibitory effect of 1,25-dihydroxyvitamin D signaling on
major inflammatory pathways results in the decreased expres-
sion of proinflammatory cytokines and chemokines in macro-
phages, dendritic cells, neutrophils, and airway epithelial cells
(Takahashi et al., 2002; Hansdottir et al., 2010; Korf et al., 2012;
Zhang et al., 2012; Ferreira et al., 2014) (Fig. 1). Therefore,
vitamin D signaling could contribute to the decreased influx
of inflammatory cells in COPD and consequently dampen the
inflammatory response. In an animal model of acute lung injury,
it has already been shown that peroral or intratracheal ad-
ministration of 1,25-dihydroxyvitamin D inhibits the recruit-
ment of neutrophils after LPS inhalation (Takano et al., 2011).
In mice, vitamin D deficiency furthermore exacerbated neutro-
phil infiltration into the lungs after challenge with Aspergillus
fumigatus (Li et al., 2014). Also, in a model of allergic airway
disease, neutrophil influx was increased in vitamin D–deficient
mice (Gorman et al., 2013). Moreover, knockout of the VDR in
mice increased neutrophilic infiltration in the lungs, which was
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accompanied by enhanced activity of NF-kB and elevated levels
of monocyte chemoattractant protein-1 and the neutrophil
chemoattractant keratinocyte chemoattractant in the lungs
(Sundar et al., 2011).
How Could Vitamin D Influence Antimicrobial De-
fense in COPD? Alveolar macrophages and neutrophils are
responsible for a broad set of host defense functions including
recognition and phagocytosis of pathogens. However, in COPD,
a growing body of evidence suggests that alveolar macrophages
and neutrophils are defective in their antimicrobial functions.
In this regard, alveolar macrophages from COPD patients show
reduced phagocytic uptake of bacteria commonly found during
exacerbations, such as Streptococcus pneumoniae and non-
typeable Haemophilus influenzae (Berenson et al., 2006;
Taylor et al., 2010).
In vitro, it was shown that cigarette smoke impairs both the
phagocytic and respiratory burst function of neutrophils, which
is necessary for the effective killing of the phagocytized material
(Green and Carolin, 1967; Stringer et al., 2007). Further, in vivo
studies in mice confirm that cigarette smoke exposure impairs
the phagocytic uptake of bacteria by alveolar macrophages,
resulting in an increased bacterial load in animals exposed to
cigarette smoke (Ortega et al., 1994; Harvey et al., 2011; Phipps
et al., 2010). This reduced phagocytic capacity of alveolar
macrophages and neutrophils in COPD may lead to chronic
colonization of the lower airways and consequently to acute
exacerbations. Macrophages from COPD patients are not only
defective in the uptake of microbes but also in the phagocytosis
of apoptotic cells (“efferocytosis”) (Hodge et al., 2003; Kirkham
et al., 2004; Hodge et al., 2007). Impaired phagocytosis of
apoptotic neutrophils leads to decreased neutrophil clearance,
and thereby increased secondary necrosis and release of toxic
cell contents, perpetuating inflammation in COPD (Vandivier
et al., 2006).
In vitro studies have shown that 1,25-dihydroxyvitamin D
can enhance the phagocytic capacity as well as the respiratory
burst functions of monocytes (Goldman, 1984; Xu et al., 1993;
Tokuda and Levy, 1996; Sly et al., 2001). The effect of vitaminD
on monocyte phagocytosis is most likely explained by the
prodifferentiating effects of vitaminD on thesemonocytes, which
adopt a more mature phenotype (Goldman, 1984). Whether
vitamin D can enhance the phagocytic uptake of microbes or
apoptotic cells by mature alveolar macrophages, which has
shown to be defective in COPD, has yet to be investigated. In
VDR knockout mice, no defects were observed in the ex vivo
phagocytic and respiratory burst capacities of peritoneal macro-
phages (Mathieu et al., 2001).
Whereas the effect of vitamin D on alveolar macrophage
phagocytosis is still debatable, vitamin Dmay certainly enhance
pulmonary antimicrobial defense by stimulating the production
of antimicrobial peptides (Korf et al., 2014) (Fig. 1). Antimicro-
bial peptides, such as cathelicidin and defensin-b2, are produced
in the lungs by several cell types, including airway epithelial
cells, macrophages, and neutrophils, and they are very effective
in killing a number of Gram-positive and -negative antibiotic-
resistant strains, such as Pseudomonas and Staphylococcus
aureus, and different viruses (Tjabringa et al., 2006). VitaminD
response elements were identified in the promoters of the
genes for both cathelicidin and defensin-b2, indicating that
1,25-dihydroxyvitamin D-VDR signaling can stimulate the tran-
scription of these genes (Wang et al., 2004). Indeed, in several cell
types includingmonocytes and neutrophils, 1,25-dihydroxyvitaminD
was shown to upregulate the expression of cathelicidin and to
a lesser extent defensin-b2, showing the potential of vitamin D
as an antimicrobial agent in COPD (Wang et al., 2004; Gombart
et al., 2005).
Several human intervention studies have demonstrated
that vitamin D supplementation reduces the risk for respiratory
tract infections (Laaksi et al., 2010; Majak et al., 2011; Bergman
et al., 2012;Manaseki-Holland et al., 2012; Gunville et al., 2013).
However, for COPD in particular, limited data are available.
Although COPD exacerbations are often caused by respiratory
infections, the association between vitamin D levels and risk of
COPD exacerbations is debatable, as several studies have
produced negative results (Kunisaki et al., 2012; Quint et al.,
2012; Puhan et al., 2014). However, preliminary results of
Bellocchia et al. (2013) have shown that severe vitamin D
deficiency increases the risk of frequent exacerbations and
hospitalizations in COPD. Moreover, in an intervention trial
with vitamin D supplementation in COPD patients, the vitamin
D–supplemented patients with severe vitamin D deficiency at
baseline showed a reduced number of exacerbations compared
with the placebo group, although no overall effect of vitamin D
supplementation on exacerbations was observed. In this in-
tervention trial, the ex vivo phagocytosis of Escherichia coli by
peripheral blood monocytes was found to be improved in COPD
patientswho had received vitaminD supplementation compared
with those receiving placebo, and these differences were evenmore
pronounced in the subgroup of patients with severe vitamin D
deficiency at baseline (Lehouck et al., 2012).
How Could Vitamin D Influence Lung Remodeling in
COPD? The chronic airflow limitation characteristic of COPD
is a result of parenchymal destruction (emphysema) and/or
small airway disease (obstructive bronchiolitis). In COPD, there
is a disruption of the balance between proteases and anti-
proteases, resulting in increased proteolytic activity in the lungs
of COPD patients. This imbalance results in the destruction of
parenchyma and thus the development of emphysema. Epithe-
lial cells, macrophages, and neutrophils release a variety of pro-
teases, including neutrophil elastase, cathepsins, and matrix
metalloproteinases (MMP). Increases in the matrix metal-
loproteinases MMP-1, MMP-2, MMP-8, MMP-9, and MMP-12
have been demonstrated in the lungs of COPD patients (Finlay
et al., 1997; Segura-Valdez et al., 2000; Molet et al., 2005).
Small airway disease in COPD includes goblet cell hyperpla-
sia, increased airway smooth muscle cells, and fibrosis in the
airway wall (Hogg, 2004). Small airway fibrosis contributes to
increased thickness of the airway wall and thereby contributes
to airflow limitation. Transforming growth factor-b (TGF-b)
plays an important role in the development of small airway
fibrosis in COPD, and expression of TGF-b has been shown to be
increased in the airway epithelium of COPD patients (de Boer
et al., 1998; Takizawa et al., 2001).
Mechanistic in vitro studies suggest that vitamin D may
influence both emphysema development and small airway
fibrosis. 1,25-Dihydroxyvitamin D has been shown to inhibit
the expression of several matrix metalloproteinases in different
cell types, including monocytes and alveolar macrophages
(Lacraz et al., 1994; Coussens et al., 2009; Bahar-Shany et al.,
2010) (Fig. 1). In an animal model, knockout of VDR led to the
development of early-onset emphysema, which was associated
with increased activity of MMP-2, MMP-9, and MMP-12 (Sundar
et al., 2011). The increased extracellular matrix formation
(including collagen) by fibroblasts in response to TGF-b takes
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part in the airway remodeling characteristic of COPD. 1,25-
Dihydroxyvitamin D has been shown to inhibit the prolifera-
tion and activation of murine fibroblasts treated with TGF-b1
and to reduce the expression of extracellular matrix proteins
by these fibroblasts (Ramirez et al., 2010) (Fig. 1). Further-
more, 1,25-dihydroxyvitamin D has also been shown to prevent
intestinal and renal fibrosis through inhibition of TGF-b signaling
(Ito et al., 2013; Tao et al., 2014).
Although fibrotic remodeling in human airways has never
been linked to vitamin D deficiency, indirect evidence may
come from epidemiologic studies showing positive associations
between serum 25-hydroxyvitamin D levels, lung function
(FEV1, forced vital capacity) both in the general population and
in COPD patients, and lung function decline (Black and Scragg,
2005; Janssens et al., 2010; Lange et al., 2012; Afzal et al.,
2014). Low serum 25-hydroxyvitamin D levels also have been
associated with the severity of computed tomography–defined
emphysema (Berg et al., 2013).
How Could Vitamin D Influence Oxidative Stress in
COPD? Oxidative stress occurs when reactive oxygen species
are produced in excess of the antioxidant defense mechanisms.
In COPD, oxidative stress results from high concentrations of
oxidants present in cigarette smoke but is also generated
endogenously from the activation of inflammatory cells in the
lungs, such as macrophages and neutrophils. Oxidative stress
is an important amplifying mechanism in COPD pathogenesis
by activating NF-kB and p38 MAPK pathways, by inhibiting
antiprotease activity, by impairing antimicrobial defenses, and
by increased release of TGF-b (Kirkham and Barnes, 2013).
Moreover, oxidative stress has been shown to contribute to the
defective ability of corticosteroids to repress inflammation in
COPD patients (Barnes, 2013).
As oxidative stress is a main player in various pathogenic
processes in COPD, therapies targeting to reduce oxidative
stress may be of crucial importance in COPD patients. A major
contributing factor to the oxidative stress in COPD is the
reduced expression of the transcription factor Nrf2 (nuclear
factor erythroid 2-related factor 2), which is activated by oxidative
stress and which is the transcriptional regulator of most
antioxidant genes. In COPD, the expression and activity of Nrf2
has been shown to be decreased despite high levels of oxidative
stress in the lungs (Goven et al., 2008; Suzuki et al., 2008).
Several studies suggest that vitaminDor vitaminDanalog therapy
may suppress oxidative stress in several disease models (Noyan
et al., 2005; Hamden et al., 2009; Husain et al., 2009; Fedirko et al.,
2010; Tanaka et al., 2011), and this could be related to the effect of
vitamin D on Nrf2 (Fig. 1). Vitamin D analogs have been shown to
activate Nrf2 in squamous carcinoma cells and myeloid leukemia
cells (Lin et al., 2002; Bobilev et al., 2011). Nakai et al. (2014) found
that treatment of diabetic rats with maxacalcitol, a vitamin D
analog, resulted in the increased expression of Nrf2 and reduced
expression of its negative regulator Keap1 (Kelch-like erythroid
cell–derived protein with CNC homology-associated protein 1),
together with suppression of NF-kB. These effects of vitamin D on
Nrf2 might also have implications for the phagocytic capacity of
alveolarmacrophages, as it has been demonstrated that restoration
of Nrf2 activity results in improved phagocytosis of H. influenzae
andPseudomonas aeruginosabyalveolarmacrophages fromCOPD
patients (Harvey et al., 2011).
Effect of Vitamin D on the Anti-Inflammatory Action
of Glucocorticosteroids in COPD. Glucocorticosteroids
(GCs) are well known for their anti-inflammatory actions.
However, inflammation in COPD has appeared to be unresponsive
to the effects ofGCs (Culpitt et al., 2003). This resistance to theanti-
inflammatory effects of GCs is a major barrier to the effective
treatment of COPD.
GCs can suppress inflammation via different mechanisms.
Binding of GCs to glucocorticoid receptors can result in the
activation of anti-inflammatory genes, including MKP-1 and
IL-10. However, the major anti-inflammatory action of GCs is
to switch off the expression of several proinflammatory genes.
In this case, glucocorticoid–glucocorticoid receptor complexes
translocate to the nucleus and recruit histone deacetylase 2.
This results in histone deacetylation, making the DNA inaccessible
for proinflammatory transcription factors, including NF-kB, and
consequently suppressing the expression of inflammatory genes.
One of most characterized molecular mechanisms contributing to
GC resistance in COPD is the decreased expression and activity
of histone deacetylase 2 in alveolar macrophages, airways, and
peripheral lung in COPD patients (Ito et al., 2004).
Interestingly, vitamin D has been shown to enhance GC
action. Zhang et al. (2012) demonstrated that vitamin D en-
hances responses to GC in human monocytes and murine bone
marrow–derived macrophages by stimulating GC-induced up-
regulation of MKP-1, leading to a decrease in the production of
proinflammatory mediators regulated by p38 MAPK (Zhang
et al., 2012). Similar results were obtained by Searing et al.
(2010), who found that levels of MKP-1 and IL-10 induced by
vitamin D plus dexamethasone (a GC) in peripheral blood mono-
nuclear cells from asthmatic children were greater than those
induced by dexamethasone alone (Searing et al., 2010). Sutherland
et al. (2010) demonstrated that reduced serum 25-hydroxyvitamin
D levels in asthmatic patients are associated with reduced
ex vivo responses of peripheral blood mononuclear cells to GCs,
as shown by a reduction in GC-induced expression of MKP-1.
Furthermore, treatment of CD41 regulatory T cells from
patients with GC-resistant asthma with 1,25-dihydroxyvitamin
D in combination with dexamethasone restored the ability of
these cells to release IL-10 up to levels similar to those in cells
from GC-sensitive asthma patients (Xystrakis et al., 2006). In the
same study, it was shown that oral administration of vitaminD
(0.5 mg/day) for 7 days to patients with GC-resistant asthma
enhanced ex vivo T-cell responses to dexamethasone. A small
clinical trial also demonstrated that a 4-week treatment with
1,25-dihydroxyvitamin D may improve the clinical responsive-
ness of GC-resistant asthma patients, as assessed by changes
in FEV1 (Nanzer et al., 2014).
This suggests that vitamin D therapy could possibly potentiate
the therapeutic response to GCs in patients with GC-resistant
asthma. Similar principles could apply in GC-resistant COPD
patients, but relevant research is limited. To our knowledge, only
one small sample size study has investigated the association
between serum 25-hydroxyvitamin D levels and responsiveness
to inhaled corticosteroid treatment, as assessed by changes in
FEV1 (Kunisaki and Rector, 2011). In this study, no correlation
was observed between baseline serum 25-hydroxyvitamin D levels
and changes in FEV1 after a short-term treatment (4 weeks) with
inhaled corticosteroids.
Therapeutic Perspectives
Due to its anti-inflammatory and antimicrobial functions
(Fig. 1), vitamin D supplementation may have a beneficial
therapeutic impact in COPD patients, in whom prevalence of
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vitamin D deficiency is high. However, various uncertainties
remain to be addressed.
Evidence from Clinical Trials. As of now, two double-
blind, randomized, placebo-controlled trials have investigated
the effect of oral vitaminD supplementation on the incidence of
exacerbations in COPD patients. In the single-center trial of
Lehouck et al. (2012), 182 COPD patients with moderate to
very severe COPD and a history of recent exacerbations were
randomized to receive a monthly oral dose of 100,000 IU
vitamin D3 or placebo for 1 year (Lehouck et al., 2012). No
overall effect of high-dose bolus vitamin D supplementation on
exacerbation rate or time to first exacerbation was observed in
the population as a whole. However, a post-hoc subgroup
analysis in a limited number of patients (n5 30) with severe
vitamin D deficiency (25-hydroxyvitamin D ,10 ng/ml) at
baseline showed a significant reduction in exacerbations in the
vitaminD–supplemented patients compared with placebo (rate
ratio 0.57, P 5 0.042).
These findings were recently confirmed by the ViDiCo trial
(Martineau et al., 2015). In this multicenter trial, 240 COPD
patients recruited from both hospital and community settings
were randomly allocated to receive a 2-monthly oral dose of 120,000
IU vitamin D3 or placebo for 1 year. Vitamin D supplementation
did not affect the time to first moderate or severe exacerbation in
the whole population. However, in accordance with the trial by
Lehouck et al. (2012), a prespecified subgroup analysis (n 5 148)
revealed that the risk of moderate or severe exacerbation was
significantly reduced in vitamin D–supplemented patients with
vitaminDdeficiency (25-hydroxyvitaminD,20 ng/ml) at baseline
(hazard ratio 0.57, P 5 0.021) compared with placebo.
The results from these two trials suggest that the benefits of
vitamin D therapy may only be seen in vitamin D–deficient
COPD patients whose 25-hydroxyvitamin D levels are elevated
over a certain threshold level by supplementation, rather than
a continual improvement with any increase in vitamin D levels.
This could also explain the lack of an overall effect in both trials.
Randomized controlled trials in COPD patients with baseline
25-hydroxyvitamin D levels below 20 ng/ml are therefore needed
to confirm these findings.
Alternatively, the overall null result in both trials may be
related to inefficient vitamin D treatment, which could in turn
be related to an ineffective dosing regimen (intermittent versus
daily dosing) or dosage form, or an inadequate route of admin-
istration, as we will discuss. Finally, the absence of a thera-
peutic effect of vitamin D in the whole study population in both
trials may be explained by COPD disease heterogeneity with
regards to pathology, immunology, and genetics, which could
modify the response of COPD patients to vitamin D supplemen-
tation (Gold and Manson, 2012).
Furthermore, preventive trials assessing the effect of
vitamin D supplementation on the risk for developing COPD
will provide better insight into the role of vitamin D in COPD
pathogenesis. In the United States, a large randomized clinical
trial among more than 20,000 participants aged 50 years or
older (lungVITAL study) is currently ongoing and will assess
the effect of daily oral vitamin D supplementation (2000 IU) with or
without fish oil (rich in omega-3 fatty acids) onpulmonary outcomes,
including new-onset COPD, decline in lung function, and COPD
exacerbations (ClinicalTrials.gov Identifier: NCT01728571).
Remaining Challenges. Although results from observa-
tional studies as well as clinical trials show therapeutic
potential for vitamin D in COPD patients, several challenges
associated with vitamin D therapy in COPD patients remain to
be addressed.
Vitamin D supplementation is mainly provided via oral supple-
ments. However, the optimal dosing regimen for oral vitamin D
supplementation, either intermittent bolus dosing or daily dosing,
remains a matter of debate. In clinical trials, intermittent bolus
doses of vitamin D are often used to maximize patient com-
pliance to the treatment. With bolus dosing, sporadic high doses
of vitamin D result in a sharp rise in 25-hydroxyvitamin D to
often supraphysiologic concentrations at the time of adminis-
tration (Ilahi et al., 2008). However, very high levels of serum
25-hydroxyvitamin D have been associated with impaired immune
responses, hypercalcemia, and even mortality (Melamed et al.,
2008; Nielsen et al., 2010; Durup et al., 2012; Martineau, 2012).
Theoretically, the high transient peaks may result in a complete
suppression of the immune system. Alternatively, high peaks
of 25-hydroxyvitamin D may upregulate catabolic enzymes
(CYP24A1), leading to local deficiency of the active metabolite after
the transient peak serum levels. To avoid supraphysiologic levels
as well as substantial fluctuations in serum 25-hydroxyvitamin D
levels, daily supplementation is likely to be preferable to a bolus
dosing regimen. Different investigators also have suggested
that intermittent bolus dosing may be less effective than daily
dosing for inducing nonclassic actions of vitamin D (Vieth,
2009; Hollis and Wagner, 2013).
Adding to the complexity of the vitamin D dosing regimen,
the levels of 1,25-dihydroxyvitamin D required to effectively
elicit immunomodulatory functions in vivo in the lungs remain
largelyunknown. Invitro studies demonstratinganti-inflammatory
and antimicrobial functions of vitamin D often use remarkably
higher concentrations of 1,25-dihydroxyvitamin D than those
found in serum. As conversion of 25-hydroxyvitamin D into
1,25-dihydroxyvitamin D can occur locally in the lungs (Monkawa
et al., 2000; Overbergh et al., 2000; Hansdottir et al., 2008; Baeke
et al., 2010) and the negative feedback mechanisms to control
this conversion appear to be absent in immune cells (Overbergh
et al., 2000; Ren et al., 2005), local concentration of
1,25-dihydroxyvitamin D within the lungs may reach relatively
higher levels in the lungs than the levels found in serum. However,
25-hydroxyvitamin D and especially 1,25-dihydroxyvitamin D
concentrations were found to be significantly lower in the
bronchoalveolar lavage (BAL) fluid compared with serum (Liu
et al., 2012; Anandaiah et al., 2013). It must be noted that
concentrations of vitamin D within the BAL fluid may not be
representative for the 1,25-dihydroxyvitamin D levels within
the entire pulmonary system. Alternatively, assessment of local
activationwithin the lungs comparedwith renal activationmay be
derived from the 1,25-dihydroxyvitaminD to 25-hydroxyvitaminD
ratio in BAL compared with this ratio in serum.
As high serum levels of vitamin D are associated with ad-
verse side effects, much effort has been made toward the de-
velopment of vitamin D analogs that still exert the beneficial
effects of vitamin D without the hypercalcemic side effects.
Unfortunately, the many vitamin D analogs that successfully
dissociate beneficial immunomodulatory functions from un-
desired side effects on calciummetabolism have not progressed
beyond the preclinical stage. Only a few vitamin D analogs are
currently on the market for the treatment of immune diseases
(Vojinovic, 2014). TX527 [19-nor-14,20-bisepi-23-yne-1,25(OH)2D3]
and maxacalcitol, two less hypercalcemic vitamin D analogs, have
already been shown to inhibit NF-kB activity in vitro in several cell
types, including monocytes (Komine et al., 1999; Stio et al., 2007;
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Gonzalez-Pardo et al., 2013), indicating the anti-inflammatory
potential of vitamin D analogs.
To reduce systemic side effects and maximize the desired
effectiveness of treatment locally in the lungs, alternative
routes of administration of vitamin D rather than peroral
administration must also be considered. In this regard, in an
animal model of acute lung injury, intratracheal administra-
tion of 1,25-dihydroxyvitamin D was found to be more effective
in dampening neutrophil recruitment into the lungs after LPS
inhalation compared with peroral administration (Takano
et al., 2011). Development of a drug for inhaled administra-
tion is a common strategy to achieve high efficiency locally in
the lungs and additionally reduce systemic side effects. Takano
et al. (2012) have demonstrated the anti-inflammatory poten-
tial of inhalational delivery of vitamin D analogs, showing that
the inhaled vitamin D analog TEI-A00114 [(5Z,7E)-(1S,3R)-20
(R)-[(5E)-(2S)-2-hydroxy-2-methyl-cyclopentanone-5-ylidene]
methyl-9,10-secopregna-5,7,10(19)-triene-1,3-diol] inhibits neu-
trophil recruitment in an animal model of acute lung injury.
Therefore, delivery of vitamin D or alternatively vitamin D
analogs via inhalation could be a promising and more directed
approach for COPD patients. Liposome encapsulation could be
an attractive delivery mode for targeting vitamin D to the lung
via inhalation. Liposomal encapsulation could prolong thera-
peutic levels locally in the lungs while reducing systemic toxicity
(Joshi and Misra, 2001; Allen and Cullis, 2013). Furthermore,
liposomal delivery could facilitate intracellular delivery of
vitamin D, particularly to phagocytes.
As vitamin D has been shown to enhance the anti-inflammatory
activities of corticosteroids (Xystrakis et al., 2006), vitamin D
may also be administered as an adjuvant therapy rather than
as a sole replacement for current therapies. This could be an
effective strategy because the majority of COPD patients are
resistant to even high doses of inhaled or oral corticosteroids. In
asthma, low serum levels of 25-hydroxyvitamin D are associ-
ated with increased corticosteroid use (Searing et al., 2010)
and reduced GC responses in vitro (Sutherland et al., 2010).
Vitamin D could not only increase the responsiveness to GCs
but may also reduce the required dose of GCs, thus limiting
the systemic side effects of GCs, including reduced bone density,
increased fracture risk, and adrenal suppression (Lipworth,
1999). Moreover, reducing the required dose of inhaled GCsmay
also dampen the dose-dependent risk for bacterial pneumonia
(Calverley et al., 2007; Ernst et al., 2007; Wedzicha et al., 2008;
Dransfield et al., 2013).
Conclusion
The airways and lung parenchyma of COPD patients are
characterized by exaggerated inflammation, increased oxida-
tive stress, impaired host defense, and lung remodeling. As
vitamin D could positively affect each of these processes,
vitamin D therapy may have great therapeutic potential in
COPD patients, who often present with vitamin D deficiency.
Appropriate antimicrobial treatment is essential in the treat-
ment of acute exacerbations of COPD. However, repetitive and
long-term treatment with antibiotics should still be avoided as
they contribute to the multiresistance of colonizing strains.
Therefore, vitamin D could be a potential alternative due to
its dual antimicrobial and anti-inflammatory properties in the
(pulmonary) immune system. Moreover, as vitamin D has been
shown to improve responsiveness to GCs, coadministration of
inhaled GCs and vitamin Dmay enhance the anti-inflammatory
effects of existing GC therapies in COPD patients. A subsequent
lower but still efficacious dose of inhaled GCs may be beneficial
by reducing the risk for pneumonia associated with high doses
(Calverley et al., 2007; Ernst et al., 2007; Wedzicha et al., 2008;
Dransfield et al., 2013).
Although an abundance of epidemiologic and mechanistic
studies support the potential benefit of vitamin D therapy in
COPD patients, more well designed trials are necessary to
unravel the potential efficacy of vitamin D therapy in COPD
patients. Here, the administration dose, form of vitamin D,
and route of administration should be taken into consideration.
Additionally, it must be noted that vitaminD therapymay only
be effective in COPD patients with defined vitamin D de-
ficiency, as demonstrated in two intervention trials with high-
dose vitamin D supplementation in COPD patients (Lehouck
et al., 2012;Martineau et al., 2015). Taken together, despite the
clear potential of vitamin D in reversing a disturbed innate
immune defense in COPD, many unknowns remain. Further
research is needed to implicate the therapeutic potential of local
upregulation of vitamin D signaling in the lungs of patients with
COPD.
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